High Dose Vitamin D May Reduce MS Activity
-
By
April 28, 2025
-
3 min
-
1
D-Lay MS trial evaluated high-dose cholecalciferol efficacy in multiple sclerosis.
-
2
The vitamin D group showed reduced disease activity compared to the placebo group.
-
3
Serious adverse events were comparable between groups.
-
4
The trial enrolled participants between 2013-2020, with follow-up until January
-
5
High-dose vitamin D may be promising for managing multiple sclerosis.
-
The D-Lay MS clinical trial in France found that high-dose oral cholecalciferol reduced disease activity in patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis, with low risk of adverse events. This vitamin D supplementation may be a promising candidate for further therapeutic strategy studies in managing multiple sclerosis.
-
1
D-Lay MS trial evaluated high-dose cholecalciferol efficacy in multiple sclerosis.
-
2
The vitamin D group showed reduced disease activity compared to the placebo group.
-
3
Serious adverse events were comparable between groups.
-
4
The trial enrolled participants between 2013-2020, with follow-up until January
-
5
High-dose vitamin D may be promising for managing multiple sclerosis.
Listen Tab content
